Lipid phosphatase SHIP2 downregulates insulin signalling in podocytes

Molecular and Cellular Endocrinology

Volumn 328, Issue 1-2, 2010, Pages 70-79

  Hyvönen, Mervi E ^a,b   Saurus, Pauliina ^a   Wasik, Anita ^a   Heikkilä, Eija ^a   Havana, Marika ^a   Trokovic, Ras ^b   Saleem, Moin ^c   Holthöfer, Harry ^a,d   Lehtonen, Sanna ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Diabetes; Diabetic nephropathy; Insulin resistance; Podocyte; Proteinuria

Indexed keywords

CD2 ASSOCIATED PROTEIN; PHOSPHATIDATE PHOSPHATASE; PROTEIN KINASE B; PROTEIN SHIP2; PROTEIN TYROSINE PHOSPHATASE SHP; PROTEIN TYROSINE PHOSPHATASE SHP DOMAIN CONTAINING INOSITOL POLYPHOSPHATE 5 PHOSPHATASE 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; ENZYME ACTIVATION; GLOMERULUS; GLUCOSE TRANSPORT; MALE; NONHUMAN; ONSET AGE; PODOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; TWO HYBRID SYSTEM; UPREGULATION;

ANIMALS; CELLS, CULTURED; DOWN-REGULATION; HUMANS; INSULIN; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORIC MONOESTER HYDROLASES; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RATS, ZUCKER; SIGNAL TRANSDUCTION;

EID: 77956340732     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.07.016     Document Type: Article

References (54)

1. Blero D., De Smedt F., Pesesse X., Paternotte N., Moreau C., Payrastre B., Erneux C. The SH2 domain containing inositol 5-phosphatase SHIP2 controls phosphatidylinositol 3,4,5-trisphosphate levels in CHO-IR cells stimulated by insulin. Biochem. Biophys. Res. Commun. 2001, 282:839-843.
2. Borch-Johnsen K., Nissen H., Henriksen E., Kreiner S., Salling N., Deckert T., Nerup J. The natural history of insulin-dependent diabetes mellitus in Denmark: 1. Long-term survival with and without late diabetic complications. Diabet. Med. 1987, 4:201-210.
3. Chua S.C., Chung W.K., Wu-Peng X.S., Zhang Y., Liu S.M., Tartaglia L., Leibel R.L. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996, 271:994-996.
4. Coimbra T.M., Janssen U., Grone H.J., Ostendorf T., Kunter U., Schmidt H., Brabant G., Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 2000, 57:167-182.
5. Coward R.J., Welsh G.I., Yang J., Tasman C., Lennon R., Koziell A., Satchell S., Holman G.D., Kerjaschki D., Tavare J.M., Mathieson P.W., Saleem M.A. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005, 54:3095-3102.
6. Dustin M.L., Olszowy M.W., Holdorf A.D., Li J., Bromley S., Desai N., Widder P., Rosenberger F., van der Merwe P.A., Allen P.M., Shaw A.S. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 1998, 94:667-677.
7. Dyson J.M., Kong A.M., Wiradjaja F., Astle M.V., Gurung R., Mitchell C.A. The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2. Int. J. Biochem. Cell Biol. 2005, 37:2260-2265.
8. Dyson J.M., O'Malley C.J., Becanovic J., Munday A.D., Berndt M.C., Coghill I.D., Nandurkar H.H., Ooms L.M., Mitchell C.A. The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates submembraneous actin. J. Cell Biol. 2001, 155:1065-1079.
9. Ellis E.N., Steffes M.W., Chavers B., Mauer S.M. Observations of glomerular epithelial cell structure in patients with type I diabetes mellitus. Kidney Int. 1987, 32:736-741.
10. Fukui K., Wada T., Kagawa S., Nagira K., Ikubo M., Ishihara H., Kobayashi M., Sasaoka T. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2) on insulin signaling and glucose metabolism in mice. Diabetes 2005, 54:1958-1967.
11. Grempler R., Zibrova D., Schoelch C., van Marle A., Rippmann J.F., Redemann N. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis. Diabetes 2007, 56:2235-2241.
12. Gropp M., Itsykson P., Singer O., Ben-Hur T., Reinhartz E., Galun E., Reubinoff B.E. Stable genetic modification of human embryonic stem cells by lentiviral vectors. Mol. Ther. 2003, 7:281-287.
13. Habib T., Hejna J.A., Moses R.E., Decker S.J. Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein. J. Biol. Chem. 1998, 273:18605-18609.
14. Hori H., Sasaoka T., Ishihara H., Wada T., Murakami S., Ishiki M., Kobayashi M. Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 2002, 51:2387-2394.
15. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
16. Huber T.B., Hartleben B., Kim J., Schmidts M., Schermer B., Keil A., Egger L., Lecha R.L., Borner C., Pavenstadt H., Shaw A.S., Walz G., Benzing T. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol. Cell. Biol. 2003, 23:4917-4928.
17. Kagawa S., Soeda Y., Ishihara H., Oya T., Sasahara M., Yaguchi S., Oshita R., Wada T., Tsuneki H., Sasaoka T. Impact of transgenic overexpression of SH2-containing inositol 5'-phosphatase 2 on glucose metabolism and insulin signaling in mice. Endocrinology 2008, 149:642-650.
18. Kaisaki P.J., Delepine M., Woon P.Y., Sebag-Montefiore L., Wilder S.P., Menzel S., Vionnet N., Marion E., Riveline J.P., Charpentier G., Schurmans S., Levy J.C., Lathrop M., Farrall M., Gauguier D. Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes 2004, 53:1900-1904.
19. Kestila M., Lenkkeri U., Mannikko M., Lamerdin J., McCready P., Putaala H., Ruotsalainen V., Morita T., Nissinen M., Herva R., Kashtan C.E., Peltonen L., Holmberg C., Olsen A., Tryggvason K. Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol. Cell 1998, 1:575-582.
20. Kim J.M., Wu H., Green G., Winkler C.A., Kopp J.B., Miner J.H., Unanue E.R., Shaw A.S. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003, 300:1298-1300.
21. Kirsch K.H., Georgescu M.M., Ishimaru S., Hanafusa H. CMS: an adapter molecule involved in cytoskeletal rearrangements. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:6211-6216.
22. Langham R.G., Kelly D.J., Cox A.J., Thomson N.M., Holthofer H., Zaoui P., Pinel N., Cordonnier D.J., Gilbert R.E. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002, 45:1572-1576.
23. Lehtonen S., Ora A., Olkkonen V.M., Geng L., Zerial M., Somlo S., Lehtonen E. In vivo interaction of the adapter protein CD2-associated protein with the type 2 polycystic kidney disease protein, polycystin-2. J. Biol. Chem. 2000, 275:32888-32893.
24. Lehtonen S., Zhao F., Lehtonen E. CD2-associated protein directly interacts with the actin cytoskeleton. Am. J. Physiol. Renal Physiol. 2002, 283:F734-F743.
25. Marion E., Kaisaki P.J., Pouillon V., Gueydan C., Levy J.C., Bodson A., Krzentowski G., Daubresse J.C., Mockel J., Behrends J., Servais G., Szpirer C., Kruys V., Gauguier D., Schurmans S. The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 2002, 51:2012-2017.
26. McClain D.A., Maegawa H., Lee J., Dull T.J., Ulrich A., Olefsky J.M. A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis. J. Biol. Chem. 1987, 262:14663-14671.
27. Meyer T.W., Bennett P.H., Nelson R.G. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999, 42:1341-1344.
28. Miyazaki Y., Cersosimo E., Triplitt C., DeFronzo R.A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int. 2007, 72:1367-1373.
29. Orchard T.J., Chang Y.F., Ferrell R.E., Petro N., Ellis D.E. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int. 2002, 62:963-970.
30. Palmen T., Lehtonen S., Ora A., Kerjaschki D., Antignac C., Lehtonen E., Holthofer H. Interaction of endogenous nephrin and CD2-associated protein in mouse epithelial M-1 cell line. J. Am. Soc. Nephrol. 2002, 13:1766-1772.
31. Parvanova A.I., Trevisan R., Iliev I.P., Dimitrov B.D., Vedovato M., Tiengo A., Remuzzi G., Ruggenenti P. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006, 55:1456-1462.
32. Pesesse X., Dewaste V., De Smedt F., Laffargue M., Giuriato S., Moreau C., Payrastre B., Erneux C. The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-stimulated COS-7 cells. J. Biol. Chem. 2001, 276:28348-28355.
33. Prasad N.K., Werner M.E., Decker S.J. Specific tyrosine phosphorylations mediate signal-dependent stimulation of SHIP2 inositol phosphatase activity, while the SH2 domain confers an inhibitory effect to maintain the basal activity. Biochemistry 2009, 48:6285-6287.
34. Saleem M.A., O'Hare M.J., Reiser J., Coward R.J., Inward C.D., Farren T., Xing C.Y., Ni L., Mathieson P.W., Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J. Am. Soc. Nephrol. 2002, 13:630-638.
35. Sasaoka T., Hori H., Wada T., Ishiki M., Haruta T., Ishihara H., Kobayashi M. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes. Diabetologia 2001, 44:1258-1267.
36. Savage D.B., Petersen K.F., Shulman G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 2007, 87:507-520.
37. Schurmans S., Carrio R., Behrends J., Pouillon V., Merino J., Clement S. The mouse SHIP2 (Inppl1) gene: complementary DNA, genomic structure, promoter analysis, and gene expression in the embryo and adult mouse. Genomics 1999, 62:260-271.
38. Sharma K., McCue P., Dunn S.R. Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Renal Physiol. 2003, 284:F1138-F1144.
39. Shih N.Y., Li J., Karpitskii V., Nguyen A., Dustin M.L., Kanagawa O., Miner J.H., Shaw A.S. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999, 286:312-315.
40. Sleeman M.W., Wortley K.E., Lai K.M., Gowen L.C., Kintner J., Kline W.O., Garcia K., Stitt T.N., Yancopoulos G.D., Wiegand S.J., Glass D.J. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat. Med. 2005, 11:199-205.
41. Steffes M.W., Leffert J.D., Basgen J.M., Brown D.M., Mauer S.M. Epithelia cell foot process width in intact and uninephrectomized diabetic and nondiabetic rats. Lab. Invest. 1980, 43:225-230.
42. Steffes M.W., Schmidt D., McCrery R., Basgen J.M. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001, 59:2104-2113. International Diabetic Nephropathy Study Group.
43. Susztak K., Raff A.C., Schiffer M., Bottinger E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55:225-233.
44. Takeda T., McQuistan T., Orlando R.A., Farquhar M.G. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J. Clin. Invest. 2001, 108:289-301.
45. Tejada T., Catanuto P., Ijaz A., Santos J.V., Xia X., Sanchez P., Sanabria N., Lenz O., Elliot S.J., Fornoni A. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int. 2008, 73:1385-1393.
46. Thorn L.M., Forsblom C., Fagerudd J., Thomas M.C., Pettersson-Fernholm K., Saraheimo M., Waden J., Ronnback M., Rosengard-Barlund M., Bjorkesten C.G., Taskinen M.R., Groop P.H. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005, 28:2019-2024. FinnDiane Study Group.
47. Tomas E., Lin Y.S., Dagher Z., Saha A., Luo Z., Ido Y., Ruderman N.B. Hyperglycemia and insulin resistance: possible mechanisms. Ann. N. Y. Acad. Sci. 2002, 967:43-51.
48. Toyoda M., Najafian B., Kim Y., Caramori M.L., Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007, 56:2155-2160.
49. Verzola D., Gandolfo M.T., Ferrario F., Rastaldi M.P., Villaggio B., Gianiorio F., Giannoni M., Rimoldi L., Lauria F., Miji M., Deferrari G., Garibotto G. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int. 2007, 72:1262-1272.
50. Wada T., Sasaoka T., Funaki M., Hori H., Murakami S., Ishiki M., Haruta T., Asano T., Ogawa W., Ishihara H., Kobayashi M. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity. Mol. Cell. Biol. 2001, 21:1633-1646.
51. Wolf G., Chen S., Ziyadeh F.N. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005, 54:1626-1634.
52. Xie J., Onnockx S., Vandenbroere I., Degraef C., Erneux C., Pirson I. The docking properties of SHIP2 influence both JIP1 tyrosine phosphorylation and JNK activity. Cell. Signal. 2008, 20:1432-1441.
53. Yip J., Mattock M.B., Morocutti A., Sethi M., Trevisan R., Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993, 342:883-887.
54. Zhang H., Saha J., Byun J., Schin M., Lorenz M., Kennedy R.T., Kretzler M., Feldman E.L., Pennathur S., Brosius F.C. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2008, 295:F1071-F1081.